Photoimmunotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Area (Head & Neck Cancer, Metastatic Melanoma, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Biotechnology & Pharmaceutical Companies, Others), and By Region 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.99 Billion
CAGR (2026-2031)	10.64%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America
Market Size (2031)	USD 3.65 Billion

Market Overview

The Global Photoimmunotherapy Market will grow from USD 1.99 Billion in 2025 to USD 3.65 Billion by 2031 at a 10.64% CAGR. Photoimmunotherapy is a targeted oncological intervention that utilizes an antibody-photosensitizer conjugate to induce specific cell necrosis upon activation by near-infrared light. The market is principally supported by the increasing prevalence of solid tumors and the clinical imperative for treatments that preserve organ function while minimizing systemic toxicity. This demand is reinforced by the substantial patient population requiring effective management for locoregional diseases. According to the American Cancer Society, in 2024, approximately 58,450 people in the United States were diagnosed with head and neck cancers, a primary indication for this modality, highlighting the urgent need for therapeutic alternatives.

However, a significant impediment to market expansion is the limited penetration depth of near-infrared light into biological tissues. This physical constraint restricts the efficacy of photoimmunotherapy to superficial or endoscopically accessible tumors, thereby complicating its application for deep-seated malignancies without invasive surgical procedures. Consequently, the technical complexity associated with light delivery systems remains a primary challenge that could hinder broader clinical adoption across diverse cancer types.

Key Market Drivers

The surge in R&D investments and the subsequent expansion of clinical pipelines are accelerating the transition of photoimmunotherapy from experimental protocols to viable commercial treatments. Financial injections are critical for sustaining late-stage trials, particularly for proprietary platforms utilizing antibody-photoabsorber conjugates that require extensive validation for regulatory bodies. According to Rakuten Medical, March 2024, in the 'Rakuten Medical Closes $119 Million Series E Financing' press release, the company secured $119 million to accelerate its global Phase 3 clinical trial of the Alluminox platform. This substantial capital influx directly supports the strategic objective of expanding the therapy's indications and achieving regulatory approvals in major markets beyond Japan, thereby validating the commercial scalability of precision cell-targeting therapies.

Simultaneously, the market is driven by the rising global prevalence of unresectable head and neck cancers, creating an urgent demand for interventions that manage locoregional disease without the morbidity of radical surgery. This driver is particularly acute in high-incidence regions where standard treatments often fail to preserve organ function. According to Rakuten Medical, January 2024, in the 'Rakuten Medical Announces First Patient Treatment in India' press release, more than 200,000 new cases of head and neck cancer are diagnosed annually in India alone, representing a critical target demographic for this modality. On a broader scale, the clinical imperative for novel solid tumor treatments is underscored by the immense global disease burden. According to the World Health Organization, February 2024, in the 'Global Cancer Burden Growing' report, there were an estimated 20 million new cancer cases worldwide in 2022, highlighting the vast addressable market for targeted therapies with reduced systemic toxicity.

Download Free Sample Report

Key Market Challenges

The limited penetration depth of near-infrared light constitutes a primary restraint on the growth of the global photoimmunotherapy market. This physical limitation largely confines the therapy's efficacy to superficial or endoscopically accessible tumors, restricting its utility for deep-seated malignancies. Consequently, the technology faces significant barriers in addressing high-volume internal cancers without complex or invasive surgical interventions. This reliance on accessibility limits the addressable patient population and complicates clinical workflows, thereby discouraging broader adoption by healthcare providers who require versatile treatment modalities for diverse oncology cases.

The impact of this constraint is evident when considering the prevalence of internal malignancies that are difficult to target with external light sources. According to the American Cancer Society, in 2024, an estimated 234,580 new cases of lung and bronchus cancer were diagnosed in the United States. The difficulty in delivering sufficient light energy to these deep tissue structures reduces the competitive advantage of photoimmunotherapy against systemic therapies. As a result, market stakeholders face challenges in positioning this modality as a primary standard of care for major internal cancer indications.

Key Market Trends

The integration of photoimmunotherapy with immune checkpoint inhibitors represents a pivotal shift towards combination regimens designed to potentiate systemic anti-tumor immunity. By inducing immunogenic cell death, photoimmunotherapy sensitizes the tumor microenvironment, thereby enhancing the efficacy of PD-1/PD-L1 inhibitors in refractory solid tumors. This synergy is clinically validated by recent data demonstrating extended survival outcomes in recurrent head and neck squamous cell carcinoma (HNSCC) patients who exhausted standard therapies. According to Rakuten Medical, September 2025, in the 'Rakuten Medical Announces Publication in Head & Neck of Phase 1b/2 Clinical Study' press release, the combination of ASP-1929 and pembrolizumab achieved a median Overall Survival (OS) of 25.6 months, significantly outperforming historical benchmarks for monotherapy.

Concurrently, the market is characterized by the strategic global expansion of clinical development programs, aiming to secure regulatory approvals across diverse geographies beyond early adopter markets. Developers are aggressively scaling pivotal trials to include multi-regional cohorts, ensuring data robustness and addressing regulatory requirements in Europe and Asia-Pacific. This trend is exemplified by the widening scope of late-stage studies for locoregional cancers, which now encompass broader patient demographics to accelerate commercial readiness. According to Rakuten Medical, July 2025, in the 'Rakuten Medical Expands Patient Recruitment to Japan' press release, the company expanded its global Phase 3 trial for recurrent HNSCC to enroll a total of 412 patients, incorporating new clinical sites in Eastern Europe to expedite recruitment and validation.

Segmental Insights

The Hospitals & Clinics segment is recognized as the fastest-growing component of the Global Photoimmunotherapy Market. This trajectory is primarily driven by the procedural complexity of the therapy, which entails a two-step process of drug infusion followed by precise laser illumination, necessitating the specialized equipment and infrastructure found in these facilities. Furthermore, the management of acute post-procedural responses, such as tumor necrosis and edema, requires the continuous professional monitoring available in hospital settings. Regulatory protocols, including approvals from bodies like Japan’s Ministry of Health, Labour and Welfare, mandate that these treatments be administered within controlled clinical environments to ensure patient safety.

Regional Insights

North America holds a dominant position in the Global Photoimmunotherapy Market, driven by its highly developed healthcare infrastructure and extensive investment in oncology research and development. The region’s leadership is reinforced by the presence of major biotechnology firms and a high concentration of clinical trials, particularly within the United States. Regulatory support further strengthens this standing; for instance, the U.S. Food and Drug Administration has granted Fast Track designation to key investigational therapies, facilitating expedited development pathways. Additionally, high healthcare expenditure and the rising prevalence of head and neck cancers create a favorable environment for the advancement and adoption of these targeted therapeutic solutions.

Recent Developments

• In June 2025, Rakuten Medical, Inc. established a strategic commercial partnership with Cyntec, a subsidiary of the OEP Group, to expand the reach of its photoimmunotherapy treatments across key Asian markets. This collaboration focused on driving the development and commercialization of the Alluminox platform in Taiwan, Singapore, Malaysia, and the Philippines, regions where head and neck cancer prevalence is notably high. The agreement, which involved upfront payments and milestone-based royalties, aimed to leverage Cyntec’s regional presence to introduce this minimally invasive therapeutic option to patients who might otherwise face limited alternatives for managing recurrent disease.
• In May 2024, Rakuten Medical, Inc. presented positive interim results from a Phase 1b/2 clinical trial evaluating its lead photoimmunotherapy asset, ASP-1929, in combination with a standard-of-care anti-PD-1 therapy. Presented at a major medical conference, the data highlighted a promising objective response rate and a manageable safety profile in patients with recurrent or metastatic head and neck squamous cell carcinoma. Following these encouraging findings, the company announced its intention to initiate a global Phase 3 trial to further investigate the clinical efficacy of this combination regimen as a potential first-line treatment option for patients suffering from this aggressive malignancy.
• In March 2024, Rakuten Medical, Inc. completed a Series E financing round, raising $119 million to advance its proprietary Alluminox platform, which serves as the foundation for its photoimmunotherapy treatments. This capital injection, supported by a global pharmaceutical company and major financial institutions, was designated to accelerate the company’s global Phase 3 clinical trial for its lead drug-device combination in head and neck cancer. Additionally, the funds were allocated to support the development of new pipeline assets and explore combination therapies, such as pairing photoimmunotherapy with anti-PD-1 inhibitors to potentially improve patient outcomes in various solid tumor indications.
• In February 2024, Modulight Corporation announced its participation in the GlioLighT project, a research initiative funded by the European Innovation Council's Pathfinder program to develop novel treatments for gliomas. The project, which received approximately EUR 2.2 million in total funding, focuses on a direct light therapy approach that generates reactive oxygen species using laser light at specific wavelengths to target difficult-to-treat brain tumors. Modulight’s specific role involves the optimization of advanced ultrashort pulse lasers to enhance optical penetration through tissue, thereby supporting the advancement of minimally invasive photoimmunotherapy and related light-activated modalities for neuro-oncology applications.

Key Market Players

• Rakuten Medical, Inc.
• Shimadzu Corporation
• Modulight Corporation
• Steba Biotech Ltd.
• Luzitin SA

By Therapeutic Area	By End User	By Region
Head & Neck Cancer Metastatic Melanoma Others	Hospitals & Clinics Ambulatory Care Centers Biotechnology & Pharmaceutical Companies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Photoimmunotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Photoimmunotherapy Market, By Therapeutic Area:

• Head & Neck Cancer
• Metastatic Melanoma
• Others

• Photoimmunotherapy Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Biotechnology & Pharmaceutical Companies
• Others

• Photoimmunotherapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE